Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.

about

Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.

Item

http://www.wikidata.org/entity/Q49898050

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Biomarker-Driven Therapy in Me ...... Real-Life Clinical Experience.

@en

Biomarker-Driven Therapy in Me ...... Real-Life Clinical Experience.

@nl

type

Item

label

Biomarker-Driven Therapy in Me ...... Real-Life Clinical Experience.

@en

Biomarker-Driven Therapy in Me ...... Real-Life Clinical Experience.

@nl

prefLabel

Biomarker-Driven Therapy in Me ...... Real-Life Clinical Experience.

@en

Biomarker-Driven Therapy in Me ...... Real-Life Clinical Experience.

@nl

P1476

Biomarker-Driven Therapy in Me ...... Real-Life Clinical Experience.

@en

P2093

Addie Dvir

http://www.w3.org/2001/XMLSchema#string

Alexander Beny

http://www.w3.org/2001/XMLSchema#string

Amichay Meirovitz

http://www.w3.org/2001/XMLSchema#string

Amiel Segal

http://www.w3.org/2001/XMLSchema#string

Andreas Voss

http://www.w3.org/2001/XMLSchema#string

Arie Figer

http://www.w3.org/2001/XMLSchema#string

Ayala Hubert

http://www.w3.org/2001/XMLSchema#string

Baruch Brenner

http://www.w3.org/2001/XMLSchema#string

David Sarid

http://www.w3.org/2001/XMLSchema#string

Diana Matceyevsky

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.

Treatment options in patients with metastatic gastric cancer: current status and future perspectives

Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study.

P2888

s11523-017-0548-8

P304

217-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-017-0548-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Dudnik

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100551818

http://www.w3.org/2001/XMLSchema#string

P698

29353436

http://www.w3.org/2001/XMLSchema#string

P932

5886994

http://www.w3.org/2001/XMLSchema#string